Cellworks Singula™ Predicts Personalized Therapy Responses for Pancreatic Cancer Patients with 94% Accuracy
myCare Study Shows Cellworks Multi-omics Biosimulation is a Superior Predictor of Therapy Response in PDAC Patients Compared to Physician Prescribed Treatment SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world …